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Abstract
Background: The common pathophysiological consequences of chronic mitral regurgitation (MR) are left atrial
(LA) remodeling/dilatation and pulmonary hypertension (PH). We aimed to study the association between LA
volume (LAV) and PH in patients with chronic organic MR.
Methods: We prospectively studied 154 patients (age 55.0 ± 16.4 years, 39.6 % female) with isolated moderate to
severe chronic organic MR. Severity of MR was assessed using proximal isovelocity surface area method. LAV was
assessed using the area-length biplane method. PH was defined as pulmonary artery systolic pressure > 50 mmHg.
Results: Ruptured chordae and flail leaflets were the most common etiology of MR (53.2 %). Severe MR
(effective regurgitant orifice area (EROA) > 40 mm2) was described in 123 (79.9 %) patients. Dyspnea, history
of heart failure and atrial fibrillation was reported in 37.7 %, 20.1 % and 29.4 % of patients, respectively.
Left ventricular (LV) ejection fraction was 68.1 ± 5.9 %. LAV index and EROA were 67.1 (24.7–391.3) ml/m2
and 60.3 (10.5–250.9) mm2, respectively. Age, presence of atrial fibrillation, EROA, LV end-systolic and end-diastolic
volume, LV mass index, LAV index and tricuspid annular plane systolic excursion were all factors univariately associated
with PH. In multiple logistic regression analysis, age (OR = 1.03, 95 % CI: 1.001-1.06, p = 0.04), EROA (OR = 1.02, 95 % CI:
1.003-1.03, p = 0.017) and LAV index (OR = 1.01, 95 % CI: 1.002-1.02, p = 0.021) were independently associated with PH.
Conclusions: In patients with chronic organic MR, a significant association exists between LAV index and PH. Age, the
severity of MR as assessed by EROA, and LAV index are the independent determinants of PH.
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Background
Mitral valve diseases, mitral stenosis and mitral regurgi-
tation (MR), remain a common health problem world-
wide. The typical pathophysiological consequences of
mitral valve diseases, regardless of the etiologies, are left
atrial (LA) dilatation and pulmonary hypertension (PH).
Organic MR is a common problem and its prevalence
increases with age [1]. Dilatation of LA, LA remodeling,
is a compensatory mechanism for the direct effect of
chronic volume overload to LA [2]. The adaptation of
LA in MR is to prevent pulmonary congestion, maintain
normal LA and pulmonary artery pressure, and avoid
PH [3]. As the severity of MR progresses, atrial fibrillation
(AF) and PH eventually occur [4, 5]. The assessment of
LA can reliably be performed using echocardiography. LA
volume (LAV) is an accurate cardiovascular risk marker in
patients with organic MR in predicting adverse outcomes
[6–8]. The presence of PH, a frequent consequence after
chronic organic MR, has prognostic implication pre-
and post-operatively [5, 9, 10]. Furthermore, recent
guidelines emphasize the clinical importance of PH,
defined as pulmonary artery systolic pressure >
50 mmHg, in asymptomatic patients with chronic se-
vere MR as an indication for early mitral valve
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surgery [11, 12]. The aim of the present study was to
determine the correlation between LAV and PH in
patients with isolated, chronic organic MR.
Methods
Study population
The study cohort consisted of consecutive patients who
were referred to the echocardiographic laboratory for
clinical evaluation of cardiac disease. An electrocardio-
gram was obtained in all patients on the day of echocar-
diography. After the results of echocardiography were
available, those with the diagnosis of isolated organic
MR were prospectively enrolled in the study. Eligible
patients were adults over 18 years of age with the diag-
nosis of chronic organic MR who had effective regurgi-
tant orifice area (EROA) of MR ≥ 20 mm2. Patients
excluded from the study were those with insignificant
MR (EROA < 20 mm2), combined mitral valve disease of
significant degree, functional/ischemic MR, previous
percutaneous balloon mitral valvotomy, associated sig-
nificant aortic valve disease (moderate to severe degree),
prosthetic valve at any position, previous cardiac or
valve surgery, left ventricular (LV) systolic dysfunction
(LV ejection fraction < 50 %), congenital or pericardial
disease, renal dysfunction (serum creatinine > 2 mg/dL),
pulmonary or hepatic disease and those with limited or
poor-quality echocardiographic study. The patients were
included in the study, regardless of symptoms. Symp-
tomatic patients were defined as those in New York
Heart Association function classes II – IV. The institu-
tional review board of Siriraj Hospital, Mahidol Univer-
sity (Bangkok, Thailand), approved the study protocol.
Informed consent was obtained from all patients.
Echocardiography
A comprehensive transthoracic echocardiographic exam-
ination consisted of two-dimensional, M-mode, Doppler
echocardiography and tissue Doppler imaging (TDI).
The average of echocardiographic measurements of 3–5
consecutive cardiac cycles was used for the analysis. The
severity of MR was quantitatively assessed using prox-
imal isovelocity surface area method and grading accord-
ing to the recommendation by American Society of
Echocardiography [13]. Patients with severe MR were
defined as those with EROA ≥ 40 mm2 and regurgitant
volume ≥ 60 ml. Tricuspid regurgitation velocity (con-
tinuous-wave Doppler) was measured to allow the calcu-
lation of pulmonary artery systolic pressure, using the
simplified Bernoulli equation [14]. Continuous-wave and
pulse-wave Doppler spectra of pulmonic regurgitation
were obtained for the determination of mean pulmonary
artery pressure, pulmonary artery end-diastolic pressure
and pulmonary vascular resistance [14–16]. PH was de-
fined as pulmonary artery systolic pressure > 50 mmHg
[11, 12]. Regarding the estimation of pulmonary pres-
sures, right atrial pressure was determined by inferior
vena cava diameter and the respiratory collapse accord-
ing to a report from the American Society of Echocardi-
ography [14]. LA diameter was determined by M-mode
echocardiography at aortic valve level of parasternal
short axis view [17]. LAV was determined using the bi-
plane area-length method and LV mass was calculated
as recommended by the American Society of Echocardi-
ography [17]. LAV and LV mass were indexed for body
surface area. The LV end-systolic and end-diastolic di-
mensions and wall thickness were measured using two-
dimensional echocardiography. The LV end-systolic and
end-diastolic volume and LV ejection fraction were
determined using the Modified Simpson’s rule (biplane)
[17]. Longitudinal systolic (Sm’) myocardial velocity,
indicating LV systolic function, was measured in apical
4-chamber view using TDI with the sample volume at
the medial mitral annulus. The LV diastolic function was
evaluated by Doppler echocardiography of transmitral
flow and TDI of the mitral annulus. Peak early (E) and
late (A) diastolic velocities of mitral inflow and deceler-
ation time of E were measured using pulsed-wave
Doppler with the sample volume at the tip of mitral
valve. The TDI determination of diastolic function was
performed in apical 4-chamber view with the sample
volume at the septal aspect of mitral annulus. Longitu-
dinal early (E’) and late (A’) diastolic myocardial veloci-
ties were measured. Right ventricular systolic function
was evaluated by assessing both the tricuspid annular
plane systolic excursion (TAPSE), determined using M-
mode echocardiography at lateral tricuspid annulus, and
the peak systolic velocity of lateral tricuspid annulus
(St’), measured by TDI.
Statistical analysis
Clinical and echocardiographic data were analyzed using
descriptive statistics, including means, standard devi-
ation, number and percentage. The Student’s t-test or
Mann Whitney U test were used to compare continuous
variables between 2 groups of patients. Comparison of
categorical variables was performed using the Chi-
square test. Spearman rank correlation was used to
relate the LAV index and the magnitude of MR, pul-
monary artery systolic pressure in all patients and the
subgroups. The Mann Whitney U test was used to com-
pare LAV index in patients with and without AF. The
receiver operating characteristic curve (ROC) analysis
was performed to determine the cutoff values of LAV
index for predicting PH. Univariate binary logistic
regression analysis was used to assess the relationship
between PH and other variables. Multiple binary logistic
regression analysis was performed using PH as the
dependent variable. Risk factors or independent variables
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(age, presence of atrial fibrillation, LV mass, LV end-
systolic and end-diastolic volume, LAV index, TAPSE
and EROA) were selected on the basis of clinical and
statistical significances. The model was fitted by back-
ward stepwise method for variable selection in and out
of the model. All p-values are reported as 2-tailed,
except where otherwise indicated. A p-value of ≤ 0.05
was considered statistically significant. Statistical ana-
lyses were performed using SPSS statistical package
version 18.0.
Results
A total of 154 patients (age 55.0 ± 16.4 years, 39.6 %
female) were enrolled in the study. The majority of
patients (62.4 %) were asymptomatic at the time of
echocardiography. Among symptomatic patients, 31.2 %,
5.2 % and 1.3 % were in New York Heart Association
functional class II, III and IV, respectively. Severe MR
and PH were reported in 123 (79.9 %) and 41 (26.6 %) of
patients, respectively. Baseline clinical characteristics in
all patients and patients grouped according to the pres-
ence of PH are shown in Table 1. Patients with PH were
older than those without. More patients with PH were
symptomatic, taking diuretic and oral anticoagulant, and
had history of heart failure. AF was reported in 45
(29.4 %) patients and more common in patients with PH
than those without (46.3 % vs. 23.2 %, p = 0.005). More
patients with PH had the abnormalities on the electro-
cardiogram (such as LA enlargement and LV hyper-
trophy by voltage criteria) than those without (41.5 % vs.
21.4 %, p = 0.013 for LA enlargement and 63.4 % vs.
38.4 %, p = 0.011 for LV hypertrophy).
Regarding the etiology of MR, ruptured chordae and
flail leaflets were the most common (53.2 %). Mitral
valve prolapse without ruptured chordae or flail leaflet,
and isolated rheumatic MR were reported in 54 (35.1 %)
and 7 (4.5 %) patients, respectively. Pulmonary artery
systolic pressure was higher in patients with severe MR
than those with non-severe MR (44.9 ± 18.7 vs. 36.3 ±
10.4 mmHg, p = 0.001). Table 2 showed echocardio-
graphic parameters of all patients and the comparisons
between patients with and without PH. The number of
patients with severe MR was significantly higher in the
group of patients with PH. Patients with PH had signifi-
cantly more severe MR as indicated by larger EROA and
regurgitant volume, larger LA and LV sizes, more LV
hypertrophy, more severe diastolic dysfunction (shorter
deceleration time, higher E/A and E/E’), more impaired
right ventricular systolic function (lower TAPSE) and
more severe tricuspid regurgitation as determined by
vena contracta width. Nevertheless, LV ejection fraction,
E’, Sm’ and St’ were not significantly different between
patients with and without PH. Table 3 demonstrated
that patients with PH had significantly larger LA size
and EROA, and more severe diastolic dysfunction
(higher E/E’), regardless of symptom.
Determinants of pulmonary hypertension
In univariate analysis, a number of factors were signifi-
cantly associated with PH, including age, AF, LV mass
Table 1 Baseline characteristics in all patients with chronic organic mitral regurgitation and the comparisons between patients with
and without pulmonary hypertension
Variables All patients (N = 154) No PH (N = 113) PH (N = 41) P-value
Age (years) 55.0 ± 16.4 53.4 ± 16.7 59.3 ± 14.8 0.050
Male gender 93(60.4) 69(61.1) 24(58.5) 0.777
Symptomatic 58(37.7) 34(30.1) 24(58.5) 0.001
BMI (kg/m2) 22.8 ± 3.4 22.6 ± 3.4 23.2 ± 3.4 0.362
Hypertension 61(39.6) 43(38.1) 18(43.9) 0.512
Diabetes mellitus 10(6.5) 8(7.1) 2(4.9) 1.0
Dyslipidemia 44(28.6) 33(29.2) 11(26.8) 0.773
Smoking 46(29.9) 36(31.9) 10(24.4) 0.371
History of HF 31(20.1) 16(14.2) 15(36.6) 0.002
Prior stroke/TIA 8(5.2) 7(6.2) 1(2.4) 0.682
Betablocker 46(30.3) 31(27.9) 15(36.6) 0.302
ACEI/ARB 56(36.8) 39(35.1) 17(41.5) 0.473
Anticoagulant 32(21.1) 19(17.1) 13(31.7) 0.050
Diuretics 65(42.8) 38(34.2) 27(65.9) <0.001
Data are expressed as mean ± standard deviation and number (percentage)
P-values are for comparisons between 2 groups
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, HF heart failure, PH pulmonary hypertension, TIA transient
ischemic attack
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index, LV end-systolic and end-diastolic volume, LAV
index, TAPSE and EROA (Table 4). By multiple regres-
sion analysis, age (p = 0.044), LAV index (p = 0.037), and
EROA (p = 0.006) remained independent predictors of
PH (Table 4 and Fig. 1). According to ROC analysis to
identify the optimal cut-off value of LAV index to pre-
dict PH, the area under the curve was 0.76. The sensitiv-
ity, specificity, predictive accuracy of positive and
negative results at different values of LAV index are
shown in Table 5.
Correlation between LAV index and pulmonary artery
systolic pressure
There was a moderate to good positive correlation between
LAV index and pulmonary artery systolic pressure (r =
0.51, p < 0.001). The correlation between LAV index and
pulmonary artery systolic pressure remained moderate to
good in the subgroup of asymptomatic patients (r =
0.59, p < 0.001), while the correlation was fair in
symptomatic patients (r = 0.36, p < 0.001). Regarding
the severity of MR, the correlations between LAV
index and pulmonary artery systolic pressure was fair
in the subgroup of patients with severe MR (r = 0.47,
p < 0.001), and moderate to good in patients without
severe MR (r = 0.54, p = 0.002). Table 6 showed the
clinical and echocardiographic comparisons according
to the symptom status and the severity of MR. Pa-
tients with severe MR or symptomatic patients were
more likely to have diastolic dysfunction (higher E/E’
ratio), higher LV mass and LAV index and higher
pulmonary artery systolic pressure than those without
severe MR or asymptomatic patients. Regarding the
magnitude of MR, there were fair positive correlations
between LAV index and EROA (r = 0.47, p < 0.001),
Table 2 Echocardiographic parameters of all patients with chronic organic mitral regurgitation and the comparisons between
patients with and without pulmonary hypertension
Variables Total (n = 154) No PH (n = 113) PH (n = 41) P-value
RVSP (mmHg) 43.2 ± 17.7 34.6 ± 7.3 66.8 ± 16.1 <0.001
PAEDP (mmHg) 14.1 ± 6.5 11.6 ± 3.8 20.8 ± 7.6 <0.001
Mean PAP (mmHg) 25.8 ± 10.3 21.5 ± 6.9 36.8 ± 9.5 <0.001
PVR (Wood unit) 2.5(1.0–9.0) 2.2(1.0–25.2) 4.0(1.9–9.0) <0.001
EROA (mm2) 61.8(22.0–250.9) 55.9(22.0–250.9) 87.5(27.0–225.1) <0.001
RVol (ml) 107.1 ± 51.8 99.1 ± 48.4 129.1 ± 55.2 0.001
Severe MR 123(79.9) 85(75.2) 38(92.7) 0.017
LVEF (%) 68.1 ± 5.9 68.4 ± 5.9 67.2 ± 6.1 0.231
LAV (ml) 109.8(44.5–653.4) 94.3(44.5–486.3) 147.1(70.9–653.4) <0.001
LAV index (ml/m2) 67.1(24.7–391.3) 59.3(24.7–276.3) 88.4(42.0–391.3) <0.001
LA diameter (mm) 52.9 ± 11.1 50.0 ± 9.6 60.8 ± 11.1 <0.001
LVDd (mm) 56.6 ± 6.7 56.2 ± 6.5 58.8 ± 6.3 0.029
LVSd (mm) 33.8 ± 5.7 33.3 ± 5.9 35.2 ± 4.8 0.072
LVEDV (ml) 113.3 ± 33.0 110.2 ± 32.2 122.0 ± 33.7 0.049
LVESV (ml) 36.5 ± 13.6 35.0 ± 13.2 40.5 ± 13.9 0.027
LVMI (g/m2) 146.4 ± 43.4 139.4 ± 38.5 165.7 ± 50.7 0.001
E (cm/sec) 119.2 ± 33.8 108.7 ± 28.6 149.0 ± 29.8 <0.001
A (cm/sec) 70.8 ± 24.1 71.1 ± 24.7 69.3 ± 21.9 0.743
E/A 1.8 ± 0.8 1.6 ± 0.7 2.3 ± 1.0 <0.001
DT (ms) 201.9 ± 48.6 208.5 ± 50.5 182.7 ± 37.1 0.005
E/E’ 15.9 ± 6.1 14.4 ± 5.3 20.7 ± 6.0 <0.001
TAPSE (mm) 22.7 ± 4.5 23.3 ± 4.3 21.2 ± 5.0 0.011
St’ (cm/sec) 12.2 ± 2.2 12.3 ± 2.0 11.7 ± 2.7 0.148
Data are expressed as number (percentage), median (min-max) or mean ± standard deviation
P-values are for comparisons between 2 groups
A peak late diastolic velocity of mitral inflow, DT, deceleration time, E peak early diastolic velocity of mitral inflow, E’ tissue Doppler peak early diastolic velocity of
medial mitral annulus, EROA effective regurgitant orifice area, LA left atrium, LAV left atrial volume, LV left ventricle, LVDd left ventricular end-diastolic diameter,
LVEF left ventricular ejection fraction, LVSd left ventricular end-systolic diameter, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic
volume, LVMI left ventricular mass index, MR mitral regurgitation, PAEDP pulmonary artery end-diastolic pressure, PAP pulmonary artery pressure, PH pulmonary
hypertension, PVR pulmonary vascular resistance, RVol regurgitant volume, RVSP right ventricular systolic pressure, St’ tissue Doppler peak systolic velocity of lateral
tricuspid annulus, TAPSE tricuspid annular plane systolic excursion
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Table 3 Baseline characteristics and echocardiographic parameters of patients with chronic organic mitral regurgitation and the
comparisons between patients with and without pulmonary hypertension in the subgroups of patients with and without symptom
Symptom (n = 58) No symptom (n = 96)
Variables No PH PH P-value No PH PH P- value
(n = 34) (n = 24) (n = 79) (n = 17)
Age (years) 59.3 ± 15.7 56.9 ± 17.1 0.580 50.9 ± 16.6 62.6 ± 10.6 0.001
Male gender 18(52.9) 12(50.0) 0.825 51(64.6) 12(70.6) 0.635
Hypertension 20(58.8) 9(37.5) 0.110 23(29.1) 9(52.9) 0.059
Diabetes mellitus 4(11.8) 1(4.2) 0.392 4(5.1) 1(5.9) 1.0
Dyslipidemia 16(47.1) 5(20.8) 0.041 17(21.5) 6(35.3) 0.228
Smoking 13(38.2) 6(25.0) 0.290 23(29.1) 4(23.5) 0.772
PAEDP (mmHg) 12.6 ± 4.8 21.0 ± 7.5 <0.001 11.3 ± 3.3 20.4 ± 8.0 <0.001
EROA (mm2) 51.0(23–251) 98.4(36–207) 0.001 56.1(22–162) 70.5(27–225) 0.250
RVol (ml) 106.3 ± 63.1 138.6 ± 54.1 0.047 96.0 ± 40.5 115.5 ± 55.6 0.096
Severe MR 24(70.6) 23(95.8) 0.019 62(78.5) 15(88.2) 0.510
LVEF (%) 68.2 ± 6.43 65.9 ± 6.0 0.169 68.6 ± 5.6 69.0 ± 5.9 0.782
LAV (ml) 93.3(50.5–286.8) 156.3(86.4–653.4) 0.001 97.2(44.5–486.3) 133.4(70.9–197.9) 0.002
LA index (ml/m2) 57.4(30.3–178.9) 98.0(54.3–391.3) 0.001 60.1(24.7–276.3) 74.1(42.0–114.1) 0.004
LA diameter (mm) 52.6 ± 8.7 63.1 ± 12.5 <0.001 48.9 ± 9.9 57.6 ± 8.0 0.001
LVDd (mm) 55.9 ± 7.2 60.2 ± 7.3 0.029 56.3 ± 6.3 56.7 ± 3.9 0.713
LVSd (mm) 32.9 ± 6.8 36.8 ± 4.7 0.018 33.5 ± 5.6 32.9 ± 4.1 0.669
LVEDV (ml) 104.7 ± 35.3 127.6 ± 34.2 0.017 112.6 ± 30.8 114.1 ± 32.3 0.855
LVESV (ml) 33.6 ± 15.3 43.8 ± 13.8 0.012 35.7 ± 12.2 35.8 ± 13.0 0.959
LVMI (g/m2) 155.6 ± 44.8 175.4 ± 56.9 0.144 132.3 ± 33.2 151.1 ± 36.5 0.046
E/E’ 16.2 ± 5.7 21.0 ± 5.8 0.006 13.6 ± 5.0 20.4 ± 6.5 <0.001
TAPSE (mm) 22.2 ± 3.9 20.5 ± 5.4 0.183 23.7 ± 4.3 22.2 ± 4.4 0.185
St’ (cm/sec) 12.2 ± 2.2 11.4 ± 2.8 0.212 12.4 ± 1.9 12.1 ± 2.5 0.551
Data are expressed as number (percentage), median (min-max) or mean ± standard deviation
P-values are for comparisons between 2 groups
A peak late diastolic velocity of mitral inflow, DT deceleration time, E peak early diastolic velocity of mitral inflow, E’ tissue Doppler peak early diastolic velocity of
medial mitral annulus, EROA effective regurgitant orifice area, LA left atrium, LAV left atrial volume, LV left ventricle, LVDd left ventricular end-diastolic diameter,
LVEF left ventricular ejection fraction, LVSd left ventricular end-systolic diameter, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic
volume, LVMI left ventricular mass index, MR mitral regurgitation, PAEDP pulmonary artery end-diastolic pressure, PAP pulmonary artery pressure, PH pulmonary
hypertension, PVR pulmonary vascular resistance, RVol regurgitant volume, RVSP right ventricular systolic pressure, St’ tissue Doppler peak systolic velocity of lateral
tricuspid annulus, TAPSE tricuspid annular plane systolic excursion
Table 4 Univariate and multivariate factors associated with pulmonary hypertension
Factors Crude odd ratio (95 % CI) P-value Adjusted odd ratio (95 % CI) P-value
Age 1.02 (1.00–1.06) 0.053 1.03 (1.001–1.06) 0.044
AF 2.86 (1.34–6.08) 0.006 -
LVMI 1.01 (1.01–1.02) 0.002 -
LVEDV 1.01 (1.0–1.02) 0.052 -
LVESV 1.03 (1.003–1.06) 0.031 -
LAV index 1.02 (1.01–1.03) 0.001 1.01 (1.001–1.02) 0.037
TAPSE 0.90 (0.82–0.98) 0.013 -
EROA 1.02 (1.01–1.03) <0.001 1.02 (1.01–1.03) 0.006
AF atrial fibrillation, CI confidence interval, EROA effective regurgitant orifice area, LAV left atrial volume, LVEDV left ventricular end-diastolic volume, LVESV left
ventricular end-systolic volume, LVMI left ventricular mass index, TAPSE tricuspid annular plane systolic excursion
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and regurgitant volume (r = 0.46, p < 0.001). Further-
more, patients with AF had a higher LAV index than
those in sinus rhythm (median 98.1 (33.9–391.3) vs.
59.7 (24.7–202.4) ml/m2, p = 0.001).
Discussion
The present study emphasizes the importance of LAV
index in the association with and as an independent de-
terminant of PH in patients with chronic organic MR.
The majority was due to chronic degenerative MR. PH
was reported in 26.6 % of patients. Patients with PH had
larger LAV than those without. Among clinical and
echocardiographic parameters, age, AF, LV mass index,
LV volume, LAV index, TAPSE and the severity of MR
were univariately associated with PH. Importantly, age,
LAV index, and the severity of MR as assessed by EROA
remained independent determinants of PH.
Left atrial enlargement and pulmonary hypertension in
chronic organic mitral regurgitation
PH is a common and frequent complication in patients
with chronic organic MR. A cutoff value of pulmonary
artery systolic pressure >50 mmHg was employed in this
study according to the current guidelines [11, 12]. Using
this value, previous studies reported PH in 23–33 % of
patients with organic MR [5, 9, 10]. Similarly, PH was
observed in 26.6 % of patients in our study. PH as a
common consequence of mitral valve disease is catego-
rized as pulmonary venous hypertension [18]. The
mechanisms of PH due to left-sided heart disease may
be multiple and complex, but the common pathway
leading to PH is presumably due to an elevated diastolic
filling pressure of the left heart [18, 19]. In the setting of
chronic elevation in the filling pressure, increased LA
pressure and LA enlargement are expected. Several en-
tities are known to result in an increased LA pressure
and LA enlargement, including LA volume/pressure
overload secondary to chronic mitral valve diseases, and
elevated LV filling pressure from LV systolic/diastolic
dysfunction. As a consequence of elevated LA pressure,
there is a passive backward transmission of pressure to
the pulmonary vascular bed, which triggers vasoconstric-
tion in the pulmonary arterial bed, leading to PH [19].
In patients with chronic organic MR, LA enlargement
and PH commonly co-exist. The regurgitant volume of
MR adds an excess volume load to LA, leading to LA
dilatation, an increased LA pressure and PH. The more
severe the MR becomes, the more likely the LAV in-
creases. Atrial fibrillation and PH eventually occur and
lead to clinical symptoms and adverse clinical outcomes.
The prognostic importance of LA enlargement and PH
in patients with chronic organic MR has been well estab-
lished [5–10]. Theoretically, LA enlargement and PH
share the ultimate pathophysiological consequences of
chronic organic MR. However, studies primarily verify-
ing the link between LA enlargement and PH in patients
with chronic organic MR are scarce. Ghoreishi M et al.
reported that higher pulmonary systolic pressure was
Fig. 1 Independent determinants of pulmonary hypertension in patients with chronic organic mitral regurgitation (EROA = effective regurgitant
orifice area; LA = left atrium; PH = pulmonary hypertension)
Table 5 Cut-off value of left atrial volume index in predicting pulmonary hypertension
Cut off of LAV index Sensitivity (%) Specificity (%) LR + LR - PPV (%) NPV(%)
≥60 ml/m2 92.7 (80.1–98.5) 50.4 (40.9–60.0) 1.9 (1.5–2.3) 0.2 (0.1–0.4) 40.4 (30.4–51.0) 95.0 (86.1–99.0)
≥65 ml/m2 85.4 (70.8–94.4) 57.5 (47.9–66.8) 2.0 (1.6–2.6) 0.3 (0.1–0.5) 42.2 (31.4–53.5) 91.5 (82.5–96.8)
≥70 ml/m2 70.7 (54.5–83.9) 63.7 (54.1–72.6) 2.0 (1.4–2.7) 0.5 (0.3–0.8) 41.4 (29.8–53.8) 85.7 (76.4–92.4)
LAV left atrial volume, LR likelihood ratio, NPV negative predictive value, PPV positive predictive value
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found in patients with a higher grade of MR, a larger LA
dimension, and more right ventricular dysfunction [9].
Barbieri A et al. demonstrated similar findings that LA
dimension was significantly higher in MR patients with
PH as compared to those without [5]. Of note, LA
dimension, not LAV, was used in those 2 studies. Le
Tourneau T et al. studied 492 patients with chronic or-
ganic MR in sinus rhythm and the majority of patients
(91 %) were asymptomatic [7]. The author found the re-
lationship between the subgroups of LAV index (<40, 40
to 59, and ≥60 ml/m2) and pulmonary artery systolic
pressure. However, recent study in asymptomatic pa-
tients with moderate or severe MR by Arias A et al.
showed that there was no statistically significant differ-
ence in pulmonary artery systolic pressure between pa-
tient with LAV index <55 and ≥55 ml/m2 [8]. The
present study confirmed the positive correlation between
LA enlargement, using LAV, and PH in patients with
MR, regardless of the presence of symptom or the severity
of MR. However, the correlations between LA enlargement
and pulmonary artery systolic pressure were fair in the sub-
groups of patients with symptoms or severe MR as com-
pared to moderate to good correlations in the subgroups
of patients without severe MR or asymptomatic patients.
The pathophysiological consequences and morphological
changes after MR are more pronounced in patients with
symptom or severe MR than in those without (Table 6).
Furthermore, the property of LA ifself, such as LA compli-
ance, is the important determinant of subsequent LA size
and the degree of pulmonary pressure during the progres-
sion of MR. These may explain the less robust correlations
between LAV index and pulmonary artery systolic pressure
in patients with more advanced disease.
Determinant of pulmonary hypertension in mitral
regurgitation
The present study is unique in demonstrating not only
the association between LAV index and PH, but also the
significance of LAV index as an independent determinant
of PH in patients with chronic organic MR. Although
there are several studies regarding the prognostic implica-
tion of LA enlargement and PH in patients with chronic
organic MR, the issue verifying the importance of LA en-
largement as an independent determinant of PH is under-
recognized. Barbieri et al. demonstrated that age and LA
size were independent predictors of PH in patients with
MR [5]. However, their study used LA dimension, instead
of LAV, and the study population was limited to those
with degenerative MR due to flail leaflet. Furthermore, Le
Tourneau T et al. emphasized the importance of LAV as
Table 6 Clinical characteristics and echocardiographic parameters of patients with chronic organic mitral regurgitation and the
comparisons between subgroups of patients according to the symptom status and the severity of mitral regurgitation





P-value Severe MR (N = 123) Non-severe MR (N = 31) P-value
Symptomatic 58 (37.7) - - - 46 (37.4) 12 (38.7) 1.0
Severe MR 123(79.9) 46 (79.3) 77 (80.2) 1.0 - - -
Age (years) 55.0 ± 16.4 58.3 ± 16.2 53.0 ± 16.3 0.051 55.3 ± 16.1 53.9 ± 17.9 0.684
Male gender 93(60.4) 30(51.7) 63(65.6) 0.087 82(66.7) 11(35.5) 0.002
Atrial fibrillation 45(29.4) 25(43.1) 20(21.1) 0.004 34(27.9) 11(35.5) 0.406
LVDd (mm) 56.9 ± 6.6 57.7 ± 7.5 56.3 ± 5.9 0.245 58.3 ± 6.3 51.1 ± 4.1 <0.001
LVSd (mm) 33.8 ± 5.7 34.5 ± 6.3 33.4 ± 5.3 0.238 34.5 ± 5.8 31.0 ± 4.4 <0.001
LVEDV (ml) 113.3 ± 33.0 114.2 ± 36.4 112.8 ± 30.9 0.810 119.5 ± 32.3 89.0 ± 22.9 <0.001
LVESV (ml) 36.5 ± 13.6 37.8 ± 15.5 35.7 ± 12.3 0.382 38.0 ± 13.8 30.4 ± 10.5 0.005
LVMI (g/m2) 146.4 ± 43.44 163.8 ± 50.7 135.5 ± 34.3 <0.001 154.6 ± 42.5 113.3 ± 29.8 <0.001
E/E’ 15.9 ± 6.1 18.0 ± 6.1 14.8 ± 5.9 0.002 16.6 ± 6.2 13.3 ± 5.0 0.008
TAPSE (mm) 22.7 ± 4.6 21.5 ± 4.6 23.4 ± 4.4 0.010 22.9 ± 4.5 22.0 ± 4.9 0.307
EROA (mm2) 61.8(22.0–250.9) 78.7(23.0–250.9) 56.5(22.0–225.1) 0.080 72.0(40.0–250.9) 28.9(22.0–44.9) <0.001
RVol (ml) 102.1(20.3–336.2) 114.8(36.2–336.2) 95.5(20.3–267.9) 0.058 113.3(61.3–336.2) 48.1(20.3–75.0) <0.001
LAV index (ml/m2) 67.1(24.7–391.3) 80.4(30.3–391.3) 62.5 (24.7–276.3) 0.007 71.7(30.3–391.3) 46.3(24.7–145.0) <0.001
RVSP (mmHg) 43.2 ± 17.7 49.0 ± 18.0 39.6 ± 16.5 0.001 44.9 ± 18.7 36.3 ± 10.4 0.001
Data are expressed as number (percentage), median (min-max) or mean ± standard deviation
P-values are for comparisons between 2 groups
E peak early diastolic velocity of mitral inflow, E’ tissue Doppler peak early diastolic velocity of medial mitral annulus, EROA effective regurgitant orifice area, LAV
left atrial volume, LVDd left ventricular end-diastolic diameter, LVSd left ventricular end-systolic diameter, LVEDV left ventricular end-diastolic volume, LVESV left
ventricular end-systolic volume, LVMI left ventricular mass index, MR mitral regurgitation, RVol regurgitant volume, RVSP right ventricular systolic pressure, TAPSE
tricuspid annular plane systolic excursion
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an independent predictor of PH and PH as an independ-
ent predictor of post-operative adverse outcomes in
patients with organic MR specifically referred for mitral
valve surgery [20]. Our findings add more evidence sup-
porting the association between LA enlargement and PH
in any patient with chronic isolated organic MR, regard-
less of cardiac rhythm, the severity, the etiology and the
timing for mitral valve surgery.
In the present study, apart from LAV index, age and
the severity of MR as assessed by EROA were found to
be the independent determinants of PH in patients with
chronic organic MR. Previous studies in general popula-
tion showed that age was associated with an increase in
pulmonary artery systolic pressure as the result of dia-
stolic dysfunction, an increased medial thickness and im-
paired elastic properties of pulmonary vessels [21, 22].
In patients with MR, the relationships between age, the
severity of MR and PH have also been reported [5, 9].
Among three independent determinants of PH reported
in the present study, it is essential to emphasize the sig-
nificance of the severity of MR as assessed by EROA as
the most powerful determinant. As expected from the
pathophysiological viewpoint and the results of the out-
come study, severe MR ultimately leads to more ad-
vanced hemodynamic alterations as evident by higher
LAV index, presence of AF, marked LV dilatation and
dysfunction, more severe PH, and impaired right ven-
tricular function, and unfavorable outcomes [5, 6].
Study limitations
The present study employed the proximal isovelocity
surface area method as the only method to determine
the severity of MR. Pulmonary artery pressure used in
this study was determined solely by Doppler echocardi-
ography, not by right heart catheterization. However, the
estimations of MR severity and pulmonary artery pres-
sure by Doppler echocardiography are reliably obtained
and the current literature supports their values in rou-
tine clinical practice [13–16]. Nevertheless, in some
difficult clinical settings, such as right heart failure or
presence of primary tricuspid regurgitation, the echocar-
diographic estimation of pulmonary artery systolic pres-
sure may be misleading. As often as is necessary for
patient’s optimal therapeutic management, right heart
catheterization with thermodilution method should be
used to achieve a more reliable estimate of pulmonary
artery systolic pressure. Although the relationship be-
tween LA enlargement and PH in patients with chronic
organic MR is theoretically expected and has already
been well established, it emphasizes the pathophysiologic
viewpoint and may not provide substantial clinical im-
pact. The generalization of the present study to all pa-
tients with chronic MR is limited and may be mainly
applied to those with chronic degenerative MR as the
majority of the study population. Furthermore, not only
the severity, but also the duration of MR is a key deter-
minant of PH and LAV in patients with MR. However, the
exact duration of MR is difficult to obtain since the history
taking itself may not be precise. Although the cut-off
values of LAV index in predicting PH were proposed in
the present study, it remains crucial to periodically assess
the change of pulmonary artery pressure and perform the
comprehensive echocardiographic examination during the
follow-up in patients with chronic organic MR.
Conclusion
In patients with chronic organic MR, a significant associ-
ation exists between LAV index and PH. Age, the severity
of MR as assessed by EROA and LAV index provide useful
information as the independent determinants of PH. This
finding supports the common pathophysiological and
hemodynamic consequences of chronic organic MR.
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